Work

BCI-838, an orally active mGluR2/3 receptor antagonist pro-drug, rescues learning behavior deficits in the PS19 MAPT mouse model of tauopathy

Year: 2023

Type: article

Source: Neuroscience Letters

DOI: 10.1016/j.neulet.2023.137080

Authors: Georgina Perez-Garcia, Mesude Bicak, Jean-Vianney Haure-Mirande, Gissel M. Perez, Alena Otero-Pagan, Miguel A. Gama Sosa, Rita De Gasperi, Mary Sano, Carrolee Barlow, Fred H. Gage, Benjamin Readhead, Michelle E. Ehrlich, Sam Gandy, Gregory A. Elder

Institutions: James J. Peters VA Medical Center, Icahn School of Medicine at Mount Sinai, Salk Institute for Biological Studies, Arizona State University

Language: English

Topic: Alzheimer's disease research and treatments

Subfield: Physiology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: U.S. Department of Veterans Affairs, Alzheimer's Drug Discovery Foundation, Pfizer, Office of Research and Development, Medpace, Cure Alzheimer's Fund, Amicus Therapeutics, Elan, National Institutes of Health, Genentech, Rehabilitation Research and Development Service, National Institute on Aging

Awards: G2370604075, G2437616791, G2882656526, G3196870201, G3225755482, G4529300044, G4638891726, G5304979608, G5888188581, G649443488, G6729029100, Arizona Alzheimer's Disease Core Center, G7902365689, UCSD Shiley-Marcos Alzheimer's Disease Research Center P30, Arizona Alzheimer's Disease Research Center, Mount Sinai Alzheimer's Disease Research Center

OpenAlex ID: W4316497490

FWCI: 1.587

Cites: 30

Cited by: 9

Related to: 10